Prognostic Significance of the Lymphocyte/Monocyte Ratio in Patients with Extensive Stage Small Cell Lung Cancer

Abstract

Purpose: Small cell lung cancer (SCLC) is a type of lung cancer that is sensitive to chemotherapy but has a poor prognosis. In this study, we aimed to investigate the prognostic significance of the lymphocyte / monocyte ratio and clinical and laboratory parameters. Materials and Methods: In this study, medical records of 146 patients who were diagnosed with SCLC between January 2014 and December 2019 and were in the extensive stage were analyzed retrospectively. The lymphocyte / monocyte ratio (LMO) was calculated from the blood tests taken before chemotherapy. Results: Median overall survival (OS) was 8.78 (range 1.07-54.80) months, progression-free survival (PFS) was 5.6 (1.07 - 44.03) months in the patients enrolled in the study. In the cohort analysis of all patients, the median PFS was 4.5 months, OS 7.5 months in the low group with LMO and 6.5 months, OS 10.1 months in the high group with LMO. When examined by univariate analysis, patients with high LMO also had longer OS than patients with low (HR 0.591 95% CI 0.42-0.83 p=0.003). When analyzed by multivariate analysis, LMO continued to be one of the good prognostic parameter for survival (HR: 0.54% 95 CI 0.38-0.77. p=0.001) Conclusion: It has been shown that high LMO can be an independent prognostic parameter showing long PFS and OS in patients with extensive stage small cell lung cancer.

Keywords

• lymphocyte/monocyte ratio
• prognostic factor
• small cell lung cancer
• survival